{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:54:51Z","timestamp":1761396891991,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02439-7","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:24:55Z","timestamp":1724426695000},"page":"357-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-0792","authenticated-orcid":false,"given":"M.","family":"Faron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Naman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Delahousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Castinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Drui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Renoult-Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Libe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Al-Ghuzlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lomb\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Paci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"For Endocan-Comete Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2439_CR1","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","volume":"26","author":"R Lib\u00e9","year":"2015","unstructured":"Lib\u00e9 R, Borget I, Ronchi CL et al (2015) Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol Off J Eur Soc Med Oncol 26:2119\u20132125. https:\/\/doi.org\/10.1093\/annonc\/mdv329","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2439_CR2","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 31:1476\u20131490. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2439_CR3","doi-asserted-by":"publisher","first-page":"e000347","DOI":"10.1136\/jitc-2019-000347","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B et al (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8:e000347. https:\/\/doi.org\/10.1136\/jitc-2019-000347","journal-title":"J Immunother Cancer"},{"key":"2439_CR4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0608","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers O, Else T et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Eur J Endocrinol"},{"key":"2439_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bjc.1994.183","volume":"69","author":"HR Haak","year":"1994","unstructured":"Haak HR, Hermans J, Velde CJ et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947\u2013951. https:\/\/doi.org\/10.1038\/bjc.1994.183","journal-title":"Br J Cancer"},{"key":"2439_CR6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","volume":"92","author":"E Baudin","year":"2001","unstructured":"Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385\u20131392","journal-title":"Cancer"},{"key":"2439_CR7","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1210\/jc.2010-2676","volume":"96","author":"IG Hermsen","year":"2011","unstructured":"Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, p\u2019DDD, o, p\u2019DDA, and o, p\u2019DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844\u20131851. https:\/\/doi.org\/10.1210\/jc.2010-2676","journal-title":"J Clin Endocrinol Metab"},{"key":"2439_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","volume":"103","author":"F Megerle","year":"2018","unstructured":"Megerle F, Herrmann W, Schloetelburg W et al (2018) Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 103:1686\u20131695. https:\/\/doi.org\/10.1210\/jc.2017-02591","journal-title":"J Clin Endocrinol Metab"},{"key":"2439_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"DL Reidy-Lagunes","year":"2017","unstructured":"Reidy-Lagunes DL, Lung B, Untch BR et al (2017) Complete responses to mitotane in metastatic adrenocortical carcinoma\u2014a new look at an old drug. Oncologist 22:1102\u20131106. https:\/\/doi.org\/10.1634\/theoncologist.2016-0459","journal-title":"Oncologist"},{"key":"2439_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-12-0368","volume":"20","author":"S Hescot","year":"2013","unstructured":"Hescot S, Slama A, Lomb\u00e8s A et al (2013) Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 20:371\u2013381. https:\/\/doi.org\/10.1530\/ERC-12-0368","journal-title":"Endocr Relat Cancer"},{"key":"2439_CR11","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1210\/en.2015-1367","volume":"156","author":"S Sbiera","year":"2015","unstructured":"Sbiera S, Leich E, Liebisch G et al (2015) Mitotane inhibits sterol-o-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 156:3895\u20133908. https:\/\/doi.org\/10.1210\/en.2015-1367","journal-title":"Endocrinology"},{"key":"2439_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0277-5379(84)90033-6","volume":"20","author":"H Slooten","year":"1984","unstructured":"Slooten H, Moolenaar AJ, Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o, p\u2019-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47\u201353","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2439_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/EJE-13-0242","volume":"169","author":"M Terzolo","year":"2013","unstructured":"Terzolo M, Baudin AE, Ardito A et al (2013) Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 169:263\u2013270. https:\/\/doi.org\/10.1530\/EJE-13-0242","journal-title":"Eur J Endocrinol"},{"key":"2439_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1677\/ERC-09-0341","volume":"17","author":"P Malandrino","year":"2010","unstructured":"Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17:797\u2013807. https:\/\/doi.org\/10.1677\/ERC-09-0341","journal-title":"Endocr Relat Cancer"},{"key":"2439_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12672-017-0313-6","volume":"9","author":"D Vezzosi","year":"2018","unstructured":"Vezzosi D, Do Cao C, Hescot S et al (2018) Time until partial response in metastatic adrenocortical carcinoma long-term survivors. Horm Cancer 9:62\u201369. https:\/\/doi.org\/10.1007\/s12672-017-0313-6","journal-title":"Horm Cancer"},{"key":"2439_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/a-0715-1946","volume":"127","author":"F Megerle","year":"2019","unstructured":"Megerle F, Kroiss M, Hahner S, Fassnacht M (2019) Advanced adrenocortical carcinoma\u2014what to do when first-line therapy fails? Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 127:109\u2013116. https:\/\/doi.org\/10.1055\/a-0715-1946","journal-title":"Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc"},{"key":"2439_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/cancers12030740","volume":"12","author":"S Puglisi","year":"2020","unstructured":"Puglisi S, Calabrese A, Basile V et al (2020) Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers 12:740. https:\/\/doi.org\/10.3390\/cancers12030740","journal-title":"Cancers"},{"key":"2439_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0041-008X(85)90266-2","volume":"77","author":"RC Pohland","year":"1985","unstructured":"Pohland RC, Counsell RE (1985) The role of high density lipoproteins in the biodistribution of two radioiodinated probes in the rat. Toxicol Appl Pharmacol 77:47\u201357","journal-title":"Toxicol Appl Pharmacol"},{"key":"2439_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00685956","volume":"29","author":"DO Gebhardt","year":"1992","unstructured":"Gebhardt DO, Moolenaar AJ, Seters AP et al (1992) The distribution of o, p\u2019-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Cancer Chemother Pharmacol 29:331\u2013334","journal-title":"Cancer Chemother Pharmacol"},{"key":"2439_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/EJE-15-0946","volume":"174","author":"M Kroiss","year":"2016","unstructured":"Kroiss M, Plonn\u00e9 D, Kendl S et al (2016) Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol 174:343\u2013353. https:\/\/doi.org\/10.1530\/EJE-15-0946","journal-title":"Eur J Endocrinol"},{"key":"2439_CR21","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1210\/JC.2015-2080","volume":"100","author":"S Hescot","year":"2015","unstructured":"Hescot S, Seck A, Guerin M et al (2015) Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma. J Clin Endocrinol Metab 100:2890\u20132898. https:\/\/doi.org\/10.1210\/JC.2015-2080","journal-title":"J Clin Endocrinol Metab"},{"key":"2439_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12672-014-0189-7","volume":"5","author":"S Hescot","year":"2014","unstructured":"Hescot S, Paci A, Seck A et al (2014) The lack of antitumor effects of o, p\u2019DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. Horm Cancer 5:312\u2013323. https:\/\/doi.org\/10.1007\/s12672-014-0189-7","journal-title":"Horm Cancer"},{"key":"2439_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2439_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41512-020-00074-3","volume":"4","author":"W Sauerbrei","year":"2020","unstructured":"Sauerbrei W, Perperoglou A, Schmid M et al (2020) State of the art in selection of variables and functional forms in multivariable analysis-outstanding issues. Diagn Progn Res 4:3. https:\/\/doi.org\/10.1186\/s41512-020-00074-3","journal-title":"Diagn Progn Res"},{"key":"2439_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","volume":"51","author":"J Bogaerts","year":"2015","unstructured":"Bogaerts J, Sydes MR, Keat N et al (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer 51:271\u2013281. https:\/\/doi.org\/10.1016\/j.ejca.2014.10.027","journal-title":"Eur J Cancer"},{"key":"2439_CR26","first-page":"1006","volume":"110","author":"RA Decker","year":"1991","unstructured":"Decker RA, Elson P, Hogan TF et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110:1006\u20131013","journal-title":"Surgery"},{"key":"2439_CR27","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","volume":"88","author":"SK Williamson","year":"2000","unstructured":"Williamson SK, Lew D, Miller GJ et al (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88:1159\u20131165","journal-title":"Cancer"},{"key":"2439_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ecl.2015.03.001","volume":"44","author":"E Baudin","year":"2015","unstructured":"Baudin E, Endocrine Tumor Board of Gustave Roussy (2015) Adrenocortical carcinoma. Endocrinol Metab Clin North Am 44:411\u2013434. https:\/\/doi.org\/10.1016\/j.ecl.2015.03.001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2439_CR29","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189\u20132197. https:\/\/doi.org\/10.1056\/NEJMoa1200966","journal-title":"N Engl J Med"},{"key":"2439_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1677\/ERC-09-0190","volume":"17","author":"B W\u00e4ngberg","year":"2010","unstructured":"W\u00e4ngberg B, Khorram-Manesh A, Jansson S et al (2010) The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 17:265\u2013272. https:\/\/doi.org\/10.1677\/ERC-09-0190","journal-title":"Endocr Relat Cancer"},{"key":"2439_CR31","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/cncr.10487","volume":"94","author":"J Abraham","year":"2002","unstructured":"Abraham J, Bakke S, Rutt A et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94:2333\u20132343. https:\/\/doi.org\/10.1002\/cncr.10487","journal-title":"Cancer"},{"key":"2439_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1530\/EJE-13-0519","volume":"169","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, Jasim S, Feng L et al (2013) Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169:891\u2013899. https:\/\/doi.org\/10.1530\/EJE-13-0519","journal-title":"Eur J Endocrinol"},{"key":"2439_CR33","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/jcm8111850","volume":"8","author":"S Puglisi","year":"2019","unstructured":"Puglisi S, Calabrese A, Basile V et al (2019) Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment. J Clin Med 8:1850. https:\/\/doi.org\/10.3390\/jcm8111850","journal-title":"J Clin Med"},{"key":"2439_CR34","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","volume":"25","author":"P Icard","year":"2001","unstructured":"Icard P, Goudet P, Charpenay C et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891\u2013897. https:\/\/doi.org\/10.1007\/s00268-001-0047-y","journal-title":"World J Surg"},{"key":"2439_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1530\/EJE-13-0142","volume":"169","author":"TMA Kerkhofs","year":"2013","unstructured":"Kerkhofs TMA, Verhoeven RHA, Bonjer HJ et al (2013) Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol 169:83\u201389. https:\/\/doi.org\/10.1530\/EJE-13-0142","journal-title":"Eur J Endocrinol"},{"key":"2439_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.mce.2014.11.027","volume":"401","author":"A Germano","year":"2015","unstructured":"Germano A, Rapa I, Volante M et al (2015) RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. Mol Cell Endocrinol 401:105\u2013110. https:\/\/doi.org\/10.1016\/j.mce.2014.11.027","journal-title":"Mol Cell Endocrinol"},{"key":"2439_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/cancers12020359","volume":"12","author":"B Altieri","year":"2020","unstructured":"Altieri B, Sbiera S, Herterich S et al (2020) Effects of germline CYP2W1*6 and CYP2B6*6 single nucleotide polymorphisms on mitotane treatment in adrenocortical carcinoma: a Multicenter ENSAT Study. Cancers 12:359. https:\/\/doi.org\/10.3390\/cancers12020359","journal-title":"Cancers"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02439-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:41:26Z","timestamp":1738334486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02439-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["2439"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02439-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"EB and RL: received honoraria from HRA Pharma.MF: received honoraria from VIFOR Pharma and travel grant from Novartis.LL: received honoraria from BAYER, EISAI, LILLY, IPSEN and ROCHE and travel grant from AAA Novartis.JH: received honoraria from BIARD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The local Ethics committee approved the study. This study complies with French law (Jarde type 3) for an observational study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was collected for each patient before inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}